The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
After receiving FDA approval, the pharmaceutical company has announced plans to launch a Phase I trial for an inhaled version of the COVID-19 treatment.
A leader with the industry association discusses the surging interest in harnessing artificial intelligence to advance various treatments and therapies.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
A representative of the research and development firm offers perspective on how the industry has shifted in recent years, thanks to a number of forces.
